# OnCo record nct03785249 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/nct03785249/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "nct03785249", "NCT03785249" ;
  schema:name "Phase 1/2 Study of MRTX849 in Patients With Cancer Having a KRAS G12C Mutation KRYSTAL-1"@en ;
  schema:alternateName "KRYSTAL-1"@en ;
  schema:description "A phase 1/2 trial of Pembrolizumab, Cetuximab, Afatinib in metastatic cancer, run by Mirati Therapeutics Inc., active and no longer recruiting."@en ;
  schema:url <https://onco.cc/trials/nct03785249/> ;
  schema:dateModified "2026-09-16"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT03785249>, <https://doi.org/10.1200/JCO.23.00434> ;
  onco:status "active" ;
  onco:tag "ctgov-ingest" ;
  onco:phase "1/2" ;
  schema:startDate "2019-01-15" ;
  onco:cancers <https://onco.cc/cancers/metastatic-cancer/>, <https://onco.cc/cancers/colorectal/>, <https://onco.cc/cancers/kras-g12c-colorectal/>, <https://onco.cc/cancers/kras-g12c-pdac/>, <https://onco.cc/cancers/pancreatic/> ;
  onco:drugs <https://onco.cc/drugs/pembrolizumab/>, <https://onco.cc/drugs/cetuximab/>, <https://onco.cc/drugs/afatinib/> ;
  onco:companies <https://onco.cc/companies/bms/> ;
  onco:terms <https://onco.cc/terms/kras-mutation-subtypes/> ;
  onco:trials <https://onco.cc/trials/codebreak-100/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-nct03785249-n-engl-j-med-2022/> .